IP Library › Granted Patent US 12,214,070
Granted Patent B2
US 12,214,070 · App. 18/185,696 · Granted Feb 4, 2025

Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins

Inventors: Antoine Decrulle (Paris, FR); Xavier Duportet (Paris, FR)
Assignee: Eligo Bioscience
A61K8/99A61K35/747A61K38/164A61K38/47A61P17/00A61Q19/005A61Q19/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,070
App. No.
18/185,696
Granted
Feb 4, 2025
Kind
B2
Abstract

A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.

Claims (18)

1. A method for killing unfavorable bacteria on a healthy skin and/or mucosa of a subject, comprising applying on said healthy skin and/or mucosa of said subject an engineered postbiotic composition comprising a microbial lysate and lysostaphin,

wherein said microbial lysate and said lysostaphin have a synergistic effect in killing unfavorable bacteria on said healthy skin and/or mucosa of said subject.

2. The method according to claim 1 , wherein said microbial lysate is obtained from GRAS and/or probiotic bacteria.

3. The method according to claim 1 , wherein said microbial lysate is obtained from bacteria isolated from a subject.

4. The method according to claim 1 , wherein said microbial lysate is obtained from Lactobacillus rhamnosus bacteria.

5. The method according to claim 1 , wherein said microbial lysate is obtained from bacteria which do not comprise any antibiotic resistance marker.

6. The method according to claim 1 , wherein said postbiotic composition comprises at least two different bacteriocins and/or endolysins.

7. The method according to claim 6 , wherein said at least two different bacteriocins and/or endolysins target the same bacterial species.

8. The method according to claim 6 , wherein said at least two different bacteriocins and/or endolysins target different bacterial species.

9. The method according to claim 1 , wherein said engineered postbiotic composition stimulates growth of at least one commensal bacterial species of the subject.

10. The method according to claim 9 , wherein said engineered postbiotic composition stimulates growth of at least one commensal bacterial species of the subject and said lysostaphin targets at least one unfavorable bacterial species.

11. A method for the care of sensitive, sensitized, fragile and/or weakened skin and/or mucosa, wherein an engineered postbiotic composition is applied on said sensitive, sensitized, fragile and/or weakened skin and/or mucosa,

wherein said engineered postbiotic composition comprises a microbial lysate and lysostaphin,

wherein said microbial lysate and said lysostaphin have a synergistic effect in killing unfavorable bacteria on said sensitive, sensitized, fragile and/or weakened skin and/or mucosa of said subject.

12. The method according to claim 11 , for the care of unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa, wherein said engineered postbiotic is applied on the skin and/or mucosa of a subject with unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa.

13. The method according to claim 11 , wherein the unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa are chosen from the feeling of heat or warmth or tension, tingling, stinging, tightness, itching, pruritus, dry patches, erythema, redness and a mixture of these manifestations.

14. The method according to claim 1 , for controlling and/or reducing body odor, wherein said engineered postbiotic composition is applied on the skin of the feet or the skin of the armpits.

15. The method according to claim 1 , wherein said engineered postbiotic composition is in the form of a cosmetic formulation for topical application.

Continuity (3)
Continuation 17698075 · Mar 18, 2022
Provisional Application 63163077 · Mar 19, 2021
Related Publication 20230218505A1 · Jul 13, 2023
References Cited (56)
US 8568714B2 · Donovan et al. · 2013 [cited by applicant]
US 11541106B2 · Decrulle et al. · 2023 [cited by applicant]
US 20020187136A1 · Loomis et al. · 2002 [cited by applicant]
US 20180325968A1 · Morris · 2018 [cited by applicant]
US 20190374621A1 · Offerhaus et al. · 2019 [cited by applicant]
US 20200254064A1 · Chumburidze · 2020 [cited by applicant]
US 20210244779A1 · O'Neill · 2021 [cited by applicant]
CN 103119158B · 2015 [cited by applicant]
CN 107412045A · 2017 [cited by applicant]
WO 2013153358A1 · 2013 [cited by applicant]
WO 2015005787A1 · 2015 [cited by applicant]
WO 2015181534A1 · 2015 [cited by applicant]
WO 2017199022A2 · 2017 [cited by applicant]
Aguilar-Toala et al. Postbiotics: An evolving term within the functional foods field. Trends in Food Science & Technology, 2018, 75, 105-114. [cited by applicant]
Jung et al. Lysates of a Probiotic, [cited by applicant]
Khaneghah et al. Interaction between probiotics and pathogenic microorganisms in hosts and foods: A review. Trends in Food Science and Technology, 2020, 95, 205-218. [cited by applicant]
Mohammedsaeed et al. Lactobacillus rhamnosus GG Inhibits the Toxic Effects of [cited by applicant]
Salminen et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Reviews: Gastroenterology and Hepatology, 2021, 18, 649-667. [cited by applicant]
Totte et al. Successful Treatment of Chronic [cited by applicant]
Liu H et al. Inhibition of [cited by applicant]
Esposito, C. Surface Level Happiness. 2020. 57(11), 62-66. [cited by applicant]
Meade, E. et al. Bacteriocins, Potent Antimicrobial Peptides and the Fight again Multi Drug Resistant Species: Resistance is Futile? Antibiotics, 2020, 9(32), 1-18. [cited by applicant]
Teame et al. Paraprobiotics and Postbiotics of Probiotic Lactobacilli, Their Positive Effects on the Host and Action Mechanisms: A Review. Frontiers in Nutrition, 2020, 7, 1-16. [cited by applicant]
Chang et al. Comparative Studies of Inhibitory and Antioxidant Activities, and Organic Acids Compositions of Postbiotics Produces by Probiotic [cited by applicant]
Abdelrahman F et al. Phage Encoded Endolysins Antibiotics, 2021, 10, 1-29. [cited by applicant]
Malashree L. et al. Postbiotics One Step Ahead of Probiotics. Int J Curr Microbiol App Scie, 2019, 8(1), 2049-2053. [cited by applicant]
Schmelcher et al. Bacteriophage Endolysins as Novel Antimicrobials, Future Microbiology, 2012, 7(10), 1147-1171. [cited by applicant]
Mohammedsaeed et al. Lactobacillus rhamnosus GG Lysate Increases Re-Epithelialization of Keratinocyte Scratch Assays by Promoting Migration. Scientific Reports, 2015, 5:16147, 1-11. [cited by applicant]
Borysowski and Gorski. Anti-Staphylococcal Lytic Enzymes. Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics by Tomas G Villa Willey & Sons, 2010, Chapter 7, 149-172. [cited by applicant]
USPTO, Office Action in U.S. Appl. No. 17/698,091, Jul. 26, 2022, 1-9. [cited by applicant]
Allain, Thibault et al. A new lactobacilli in vivo expression system for the production and delivery of heterologous proteins at mucosal surfaces, FEMS Microbiology Letters, vol. 363, Issue 13, Jul. 2016, 1-9. [cited by applicant]
Bouslimani, Amina et al. Molecular catography of the human skin surface in 3D. Pnas. Mar. 6, 2015. E2120-E2129. [cited by applicant]
Bouslimani, Amina et al. The impact of skin care products on skin chemistry and microbiome dynamics. BMC Biology, 17, 47 (2019) 1-20. https://doi.org/10.1186/s12915-019-0660-6. [cited by applicant]
Briers, Yves et al. A standardized approach for accurate quantification of murein hydrolase activity in high thyoughput assays. Journal of Biochemical and Biophysics Methods. 2007. 531-533. [cited by applicant]
Byrd, Allyson et al. The Human Skin Microbiome. Nature Reviews Microbiology. 16, 143-155 (2018). https://doi.org/10.1038/nrmicro.2017.157. [cited by applicant]
Chrowdhury, Sreyan et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity.Nature Medicine. 1057-1063 (2019). https://doi.org/10.1038/s41591-019-0498-z. [cited by applicant]
Cotter, Paul. Bacteriocins: Developing innate immunity for food. Nature Reviews Microbiology. Oct. 2005, 3 (10), 777-788. doi:10.1038/nrmicro 1240. [cited by applicant]
Donovan, David M et al. Lysis of staphylococcal mastitis pathogens by bateriophage phi11 endolysin. FEMS Microbiol Lett. Dec. 2006; 265(1):133-9. doi: 10.1111/j.1574-6968.2006.00483.x. [cited by applicant]
Fernandez-Ruiz, Iris et al. Thousands of novel endolysins discovered in uncultured phage genomes. Frontiers in Microbiology. May 18, 2018. 1-8. https://doi.org/10.3389/fmicb.2018.01033. [cited by applicant]
Gervasi, T et al. Application of Lactobacillus johnsonii expressing phage endolysin for control of Clostridium perfringens. Letter's in Applied Microbiology. 2014. 59, 355-361. [cited by applicant]
Gervasi, Teresa et al. Expression and delivery of an endolysin to combat Clostridium perfringens. Applied Microbiology Biotechnology, 2014. 98. 2495-2505. DOI 10.1007/s00253-013-5128-. [cited by applicant]
Grice, E. et al. Topographical and temporal diversity of the human skin microbiome. Science. May 29, 2009; 324 (5931): 1190-1192. doi:10.1126/science.1171700. [cited by applicant]
Grice, Elizabeth and Julia Segre. The skin microbiome. Nat Rev Microbiol. Apr. 2011 ; 9(4): 244-253. doi:10.1038/nrmicro2537. [cited by applicant]
Gurbatri, Candice et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. Feb. 12, 2020; 12(530): . doi:10.1126/scitranslmed.aax0876. [cited by applicant]
Heenan, C.N., Growth medium for culturing probiotic bacteria for applications in vegetarian food products. LWT Food Science and Technology. (2002), 35, 171-176. [cited by applicant]
Kong, Heidi H and Julia A Segre. Skin microbiome: looking back to move forward. Journal of Investigative Dermatology (2012) 132, 933-939; doi:10.1038/jid.2011.417. [cited by applicant]
Kurtz, Caroline et al. An engineered E.coli nissle improves hyperammonemia and survival in mice and shoes does—dependent exposure in healthy humans. Science Translational Medicine. Jan. 16, 2019, 11 1-14. [cited by applicant]
Leshem Avner et al. Immune-microbiota interplay and colonization resistance in infection. Molecular Cell. May 21, 2020. 78(4). 597-613. [cited by applicant]
Liu, Huanli et al. Inhibition of [cited by applicant]
Myers, Eugene and Webb Miller. Optimal alignments in linear space. CABIOS. 4(1). 1998. 11-17. [cited by applicant]
Needleman, Saul B and Christian Wunsch. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol (1970). 48, 443-453. [cited by applicant]
Ohland, Christina L and Wallace K. MacNaughton. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298: G807-G819, 2010. doi:10.1152/ajpgi.00243.2009. [cited by applicant]
Sfriso, R. et al. Revealing the secret life of skin—with the microbiome you never walk alone. International Journal of Cosmetic Science, 2020, 42, 116-126. [cited by applicant]
Sorvig, Elisabeth et al. High-level, inducible gene expression in Lactobacillus sakei and Lactobacillus plantarum using versatile expression vectors. Microbiology (2005), 151, 2439-2449. DOI 10.1099/mic.0.28084-0. [cited by applicant]
Suez, Jotham et al. The pros, cons, and many unknowns of probiotics. Nature Medicine. (2019), 25, 716-729. [cited by applicant]
Turner, Mark S et al. Antimicrobial activity of lysostaphin and a Listeria monocytogenes bacteriophage endolysin produced and secreted by lactic acid bacteria. Systematic and Applied Microbiology 30 (2007) 58-67. [cited by applicant]